News | December 13, 2011

MBI Enhances Pre-Surgical Planning For Patients With Newly Diagnosed Breast Cancer

December 13, 2011 – According to a new study, molecular breast imaging (MBI), can provide critical information in the initial diagnostic workup and surgical planning for patients with newly diagnosed breast cancer. Adding MBI to conventional imaging, namely mammography and ultrasound, enhances pre-surgical planning.

In a retrospective review of records at Scripps Clinic (San Diego, Calif.), MBI confirmed, clarified or added to findings of conventional imaging in 75 percent of patients. MBI identified an additional lesion or significantly changed management in 20 percent of cases. MBI was unhelpful or led to an additional nine biopsies or work-up in 25 percent of patients. The study concludes that MBI was found to be cost-effective, well-tolerated and was a reasonably sensitive and specific adjunct modality for enhancing pre-surgical planning for patients with newly diagnosed breast cancer, especially in relatively young female patients with dense breast tissue. For this study MBI was conducted with a high-resolution gamma camera, the Dilon 6800.

"Based on our review of our first year's experience with breast cancer patients who had BSGI prior to undergoing cancer treatment surgery, we have a better understanding of the modality's strengths and limitations," said Marie Tartar, M.D., of Scripps Health.

"Like all breast imaging modalities, MBI will not identify all cancers. However, we have found in selected patients needing further evaluation for persistent questions after conventional breast imaging work-up (mammogram and/or ultrasound), MBI can be useful and may be the first modality to indicate the presence of a breast cancer. Based on our results, MBI seems to be an acceptable alternative to pre-operative local staging of breast cancer, if additional imaging beyond mammography and ultrasound is indicated, and a patient cannot or prefers not to undergo MRI [magnetic resonance imaging]," said Tartar.

As a follow-up to mammography, MBI utilizes the Dilon 6800 gamma camera to help physicians more clearly differentiate benign from malignant tissue. To perform MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal healthy cells and generally appear as dark spots on the MBI image.

For more information: www.dilon.com

Related Content

Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Overlay Init